These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 28576415)

  • 1. Stem cell contributions to neurological disease modeling and personalized medicine.
    Liang N; Trujillo CA; Negraes PD; Muotri AR; Lameu C; Ulrich H
    Prog Neuropsychopharmacol Biol Psychiatry; 2018 Jan; 80(Pt A):54-62. PubMed ID: 28576415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploiting urine-derived induced pluripotent stem cells for advancing precision medicine in cell therapy, disease modeling, and drug testing.
    Yin X; Li Q; Shu Y; Wang H; Thomas B; Maxwell JT; Zhang Y
    J Biomed Sci; 2024 May; 31(1):47. PubMed ID: 38724973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advancing drug discovery for neuropsychiatric disorders using patient-specific stem cell models.
    Haggarty SJ; Silva MC; Cross A; Brandon NJ; Perlis RH
    Mol Cell Neurosci; 2016 Jun; 73():104-15. PubMed ID: 26826498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genome engineering of stem cell organoids for disease modeling.
    Sun Y; Ding Q
    Protein Cell; 2017 May; 8(5):315-327. PubMed ID: 28102490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genome Editing and Induced Pluripotent Stem Cell Technologies for Personalized Study of Cardiovascular Diseases.
    Chun YW; Durbin MD; Hong CC
    Curr Cardiol Rep; 2018 Apr; 20(6):38. PubMed ID: 29666931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concise review: modeling central nervous system diseases using induced pluripotent stem cells.
    Zeng X; Hunsberger JG; Simeonov A; Malik N; Pei Y; Rao M
    Stem Cells Transl Med; 2014 Dec; 3(12):1418-28. PubMed ID: 25368377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigating pediatric disorders with induced pluripotent stem cells.
    Durbin MD; Cadar AG; Chun YW; Hong CC
    Pediatr Res; 2018 Oct; 84(4):499-508. PubMed ID: 30065271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient and Disease-Specific Induced Pluripotent Stem Cells for Discovery of Personalized Cardiovascular Drugs and Therapeutics.
    Paik DT; Chandy M; Wu JC
    Pharmacol Rev; 2020 Jan; 72(1):320-342. PubMed ID: 31871214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential of Gene Editing and Induced Pluripotent Stem Cells (iPSCs) in Treatment of Retinal Diseases.
    Chuang K; Fields MA; Del Priore LV
    Yale J Biol Med; 2017 Dec; 90(4):635-642. PubMed ID: 29259527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induced Pluripotent Stem Cells (iPSCs) in Developmental Toxicology.
    Easley CA
    Methods Mol Biol; 2019; 1965():19-34. PubMed ID: 31069666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induced Pluripotent Stem Cells for Cardiovascular Disease Modeling and Precision Medicine: A Scientific Statement From the American Heart Association.
    Musunuru K; Sheikh F; Gupta RM; Houser SR; Maher KO; Milan DJ; Terzic A; Wu JC;
    Circ Genom Precis Med; 2018 Jan; 11(1):e000043. PubMed ID: 29874173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug discovery using induced pluripotent stem cell models of neurodegenerative and ocular diseases.
    Hung SSC; Khan S; Lo CY; Hewitt AW; Wong RCB
    Pharmacol Ther; 2017 Sep; 177():32-43. PubMed ID: 28223228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Developing precision medicine using scarless genome editing of human pluripotent stem cells.
    Steyer B; Cory E; Saha K
    Drug Discov Today Technol; 2018 Aug; 28():3-12. PubMed ID: 30205878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human pluripotent stem cell-derived models and drug screening in CNS precision medicine.
    Silva MC; Haggarty SJ
    Ann N Y Acad Sci; 2020 Jul; 1471(1):18-56. PubMed ID: 30875083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of induced pluripotent stem cell technology for the investigation of hematological disorders.
    Dolatshad H; Tatwavedi D; Ahmed D; Tegethoff JF; Boultwood J; Pellagatti A
    Adv Biol Regul; 2019 Jan; 71():19-33. PubMed ID: 30341008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new era of disease modeling and drug discovery using induced pluripotent stem cells.
    Suh W
    Arch Pharm Res; 2017 Jan; 40(1):1-12. PubMed ID: 27921262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human iPSC-Based Modeling of Central Nerve System Disorders for Drug Discovery.
    Qian L; Tcw J
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33530458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modeling neurological diseases using iPSC-derived neural cells : iPSC modeling of neurological diseases.
    Li L; Chao J; Shi Y
    Cell Tissue Res; 2018 Jan; 371(1):143-151. PubMed ID: 29079884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induced Pluripotent Stem Cells in Disease Modeling and Gene Identification.
    Kumar S; Blangero J; Curran JE
    Methods Mol Biol; 2018; 1706():17-38. PubMed ID: 29423791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stem cells: A path towards improved epilepsy therapies.
    Lybrand ZR; Goswami S; Hsieh J
    Neuropharmacology; 2020 May; 168():107781. PubMed ID: 31539537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.